Top 5 Papers
#1
Source: Lancet Oncology | Authors: Hu H, Deng Y, et al. (multicentre, 3 academic hospitals, China) | Published: July 1, 2026
Score: 14/20 — Base 9 (Lancet Oncology) + Phase II (+2) + biomarker-guided/precision, dMMR/MSI-H selection (+1) + Colleague Engagement (+2: independently posted by @DrRishabhOnco and @DaisukeKotani)
This open-label, multicentre phase 2 trial randomized 110 patients with dMMR/MSI-H locally advanced colorectal cancer to neoadjuvant toripalimab plus the COX-2 inhibitor celecoxib versus toripalimab alone before surgery. The combination raised pathological complete response to 89% (49/55) versus 69% (38/55) — a 19-point absolute gain (95% CI 4-34, p=0.014). Grade 3 treatment-related adverse events were uncommon in both arms, with no grade 4/5 events reported. PICC-2 suggests a cheap, oral partner can push already-impressive neoadjuvant immunotherapy pCR rates in dMMR colon cancer even higher, strengthening the organ-preservation conversation.
Post angle: A cheap oral COX-2 inhibitor lifts neoadjuvant IO pCR from 69% to 89% in dMMR/MSI-H CRC. Watch the organ-preservation implications. #GIOnc #CRC #PrecisionMedicine
#2
Source: Lancet Oncology | Authors: Rovers KP, de Hingh IHJT, et al. (multicentre, 10 Dutch/Belgian centres) | Published: July 1, 2026
Score: 12/20 — Base 9 (Lancet Oncology) + Phase III RCT (+3). Negative trial (no OS benefit, HR 0.85, p=0.28) so no survival-benefit or new-SOC bonus.
CAIRO6 randomized 358 patients with resectable colorectal peritoneal-only metastases to perioperative systemic therapy plus CRS-HIPEC versus upfront CRS-HIPEC alone. Median overall survival was 44 versus 39 months (HR 0.85, 95% CI 0.62-1.15, p=0.28) — no significant benefit — while major 90-day morbidity was higher with perioperative chemotherapy (36% vs 26%). This is an important negative result: it argues against reflexively giving perioperative chemotherapy to all comers with resectable peritoneal disease, and refocuses the decision on patient selection rather than blanket application.
Post angle: A powered phase 3 negative trial: perioperative chemo adds no OS benefit (and more morbidity) over upfront CRS-HIPEC in resectable colorectal peritoneal mets. Select, don't reflex. #GIOnc #CRC
#3
Source: BMJ | Authors: Jin J, Shen B, et al. (multicentre, 7 high-volume centres, China) | Published: July 1, 2026
Score: 9/20 — Base 6 (BMJ, high-impact general medical journal) + Phase III non-inferiority RCT (+3)
PORTAL is the first adequately powered multicentre phase 3 non-inferiority RCT comparing robotic versus open pancreatoduodenectomy, enrolling 268 patients across seven high-volume Chinese centres. The robotic approach met non-inferiority and shortened the restricted mean time to functional recovery to 12.1 versus 16.0 days (difference -3.9 days, 95% CI -5.6 to -2.2, p<0.001), with shorter length of stay but higher cost and longer operative time. Oncologic and safety outcomes were comparable. For pancreatic surgical oncology, PORTAL provides the randomized evidence the robotic-versus-open debate has long lacked.
Post angle: Robotic Whipple finally gets its phase 3: non-inferior to open, faster functional recovery (12.1 vs 16.0 days), comparable oncologic outcomes. Now it's about access and cost, not efficacy. #GIOnc #PDAC
#4
Source: JAMA Oncology | Authors: Oussalah A, Bronowicki JP, et al. (SEPT9_CROSS Study Group, France) | Published: July 2, 2026
Score: 8/20 — Base 7 (JAMA Oncology, diagnostic-accuracy study, not an RCT so no study-type bonus) + biomarker-guided/precision (+1)
This prospective diagnostic-accuracy study (n=574 cirrhosis patients under HCC surveillance) tested circulating methylated SEPT9 against alpha-fetoprotein. Methylated SEPT9 outperformed AFP (AUROC 0.79 vs 0.71, p=0.002), and a tiered rule reached 87.8% overall sensitivity — critically, 74.5% sensitivity for early-stage BCLC 0-A disease versus just 23.5% for AFP alone, a 3.2-fold improvement where it matters most. If validated prospectively, a methylation-based blood test could meaningfully close AFP's well-known early-detection gap in cirrhosis surveillance.
Post angle: AFP misses most early HCC. Methylated SEPT9 triples early-stage (BCLC 0-A) sensitivity vs AFP (74.5% vs 23.5%) in cirrhosis surveillance. A blood test worth validating. #GIOnc #HCC #LiverCancer
Additional Papers of Interest
-
Annals of Oncology — Multicentre AI model diagnoses intrahepatic cholangiocarcinoma from histology with a calibrated confidence threshold, flagging low-confidence cases for pathologist review
-
Journal of Hematology & Oncology — CLDN18.2-targeted CAR T-cell therapy achieves durable control of peritoneal disease in heavily pretreated advanced gastric cancer
-
Cancer Causes & Control — Behavioral-economics framing in mailed FIT outreach improves colorectal cancer screening return rates in a randomized trial
-
Journal of Medical Internet Research — Meta-analysis of randomized trials finds immersive VR reduces symptom burden in GI cancer patients
Back to all digests